---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-028650"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T16:32:51.199625+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Stoke and Biogen enter $165M upfront collaboration for zorevunersen (Dravet syndrome)

## Summary
- Stoke receives $165M upfront; eligible for up to $385M in milestones and low-double-digit to high-teen royalties.
- Stoke retains exclusive rights in US, Canada, Mexico; Biogen gets rest-of-world commercialization rights.
- Phase 3 EMPEROR study to start Q2 2025 with pivotal data readout expected 2H 2027.
- Cash runway extended to mid-2028, including upfront payment and other eligible cash flows.
- Zorevunersen has FDA Breakthrough Therapy designation; Phase 1/2a showed substantial seizure reduction and cognitive improvements.

## SEC filing metadata
- accession: 0001193125-25-028650
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312525028650/0001193125-25-028650-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312525028650/d889348d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-028650
- JSON: https://secwatch.observer/filing/0001193125-25-028650.json
- Plain text: https://secwatch.observer/filing/0001193125-25-028650.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.